Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

Lucy Pickard, Li Yuan Chan, Su Li, Michael Potter, Emma Nicholson, Ian Chau, David Cunningham, Juanah Addada, Emily Chernucha, Sunil Iyengar, Dima El-Sharkawi

Blood (2024) 144 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2024-204653

Published: 2024

Journal Articles

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Dima El-Sharkawi, Tasneem Elnafie, Sarah Thompson, Louise Stanton, Nicholas Counsell, Amit Sud, Ian Chau, Bhupinder Sharma, Peter Johnson, David C. Linch, Sunil Iyengar, Andrew Davies, David Cunningham

Blood (2022) 140 (Supplement 1): 7908–7909.

https://doi.org/10.1182/blood-2022-167852

Published: 2022

Journal Articles

Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

Farheen Mir, Anna Robinson, Mark Edward Ethell, Michael Potter, Emma Nicholson, Chloe Anthias, Sandra Easdale, Carlos Gonzalez-Arias, Amit Sud, Claire E. Dearden, Ian Chau, David Cunningham, Dima El-Sharkawi, Bhupinder Sharma, Sunil Iyengar

Blood (2022) 140 (Supplement 1): 9366–9367.

https://doi.org/10.1182/blood-2022-166198

Published: 2022

Journal Articles

The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL

Sarah Thompson, Tasneem Elnafie, Tatiana Elwes, Wilam Alfred, Alinane Munyenyembe, Kabir Mohammed, Bhupinder Sharma, MBBS, BSc(Hons) BM FRCR, Ian Chau, MD, David Cunningham, MD FRCP, FMedSci, Sunil Iyengar, MD FRCPath, PhD, Dima El-Sharkawi

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141982

Published: 2020

Journal Articles

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Blood (2019) 134 (Supplement_1): 2879.

https://doi.org/10.1182/blood-2019-122830

Published: 2019

Journal Articles

Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience

Vasiliki Michalarea, MD, Dima El-Sharkawi, MBBS BSc FRCPath MD, Siraj Yusuf, Mary Gleeson, Laura Hickmott, Andrew Wotherspoon, Ayoma Attygalle, Simon O'Connor, Bhupinder Sharma, Yong Du, Imene Zerizer, Alan Horwich, Gillian Ross, Andrea Kuhnl, Sunil Iyengar, Ian Chau, MD, David Cunningham

Blood (2018) 132 (Supplement 1): 4240.

https://doi.org/10.1182/blood-2018-99-119560

Published: 2018

Journal Articles

Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma

Blood (2018) 132 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2018-99-117932

Published: 2018

Journal Articles

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Blood (2017) 130 (Supplement 1): 2771.

https://doi.org/10.1182/blood.V130.Suppl_1.2771.2771

Published: 2017

Journal Articles

R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial

Andrea Kuhnl, MD, Clare Peckitt, Bijal Patel, Kirit M Ardeshna, MD, Marian P Macheta, John Radford, MD, Rod Johnson, Shankaranarayana Paneesha, Sarah Barton, Ian Chau, MD, Martin F Kaiser, MD, Ruwaida Begum, Nicola Valeri, Andrew Wotherspoon, Yong Du, Imene Zerizer, David Cunningham, MD FRCP

Blood (2017) 130 (Supplement 1): 2829.

https://doi.org/10.1182/blood.V130.Suppl_1.2829.2829

Published: 2017

Journal Articles

Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma

Charlotte Wilding, BSc, MBChB, Farheen Mir, MBBS, Indu Mitra, Bhupinder Sharma, Larissa Sena, Andrew Wotherspoon, David Cunningham, MD FRCP, Ian Chau, MD, Claire E. Dearden, MD FRCP, FRCPath, Kabir Mohammed, Sunil Iyengar

Blood (2017) 130 (Supplement 1): 2786.

https://doi.org/10.1182/blood.V130.Suppl_1.2786.2786

Published: 2017

Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD

Blood (2017) 130 (Supplement 1): 1554.

https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554

Published: 2017

Journal Articles

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Blood (2016) 128 (22): 480.

https://doi.org/10.1182/blood.V128.22.480.480

Published: 2016

Journal Articles

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Blood (2016) 128 (22): 624.

https://doi.org/10.1182/blood.V128.22.624.624

Published: 2016

Journal Articles

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

Noopur Raje, Ian Chau, David M. Hyman, Vincent Ribrag, Jean-Yves Blay, Josep Tabernero, Maria Elena Elez-Fernandez, Jürgen S. Wolf, Florin Sirzen, Andrew Yee, Jason Faris, Martin Kaiser, Heather Landau, Jean-Marie Michot, Luisa Veronese, Martina Makrutzki, Susan Francis Lasserre, Igor Puzanov, Jose Baselga

Blood (2015) 126 (23): 4263.

https://doi.org/10.1182/blood.V126.23.4263.4263

Published: 2015

Journal Articles

Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Blood (2015) 126 (23): 1499.

https://doi.org/10.1182/blood.V126.23.1499.1499

Published: 2015

Journal Articles

Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013

Mary Gleeson, FRCPath, Eliza A Hawkes, MD, Clare Peckitt, MSc, Andrew Wotherspoon, FRCPath, Ayoma Attygalle, PhD, Bhupinder Sharma, MD, Yong Du, MD, Mark Ethell, MD, Michael Potter, PhD, Claire Dearden, MD, Alan Horwich, MD, Ian Chau, MD, David Cunningham, FMedSci

Blood (2014) 124 (21): 1719.

https://doi.org/10.1182/blood.V124.21.1719.1719

Published: 2014

Journal Articles

Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [ 18 f]FDG-PET Prior to Allogeneic Transplant

Robert N Lown, MBBS, MDRes), MRCP, FRCPath, Anastasia Constantinidou, Caroline Ebdon, Kabir Mohammed, Mark Ethell, MD, Ian Chau, MD, David Cunningham, FMedSci, Michael Potter, PhD, Bhupinder Sharma, MD

Blood (2014) 124 (21): 1249.

https://doi.org/10.1182/blood.V124.21.1249.1249

Published: 2014

Journal Articles

Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma

Blood (2014) 124 (21): 3971.

https://doi.org/10.1182/blood.V124.21.3971.3971

Published: 2014

NARROW

Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience

Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial

Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013

Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [ 18 f]FDG-PET Prior to Allogeneic Transplant

Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only